ReviewHeart failure reviews2018
Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions.
Review in Heart failure reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.Journal of the American College of Cardiology · 2023Guideline
- A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF.Clinical pharmacokinetics · 2026Trial
- A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2023Trial
- Guideline-Directed Heart Failure Pharmacotherapy in Adults Aged ≥75 Years: Evidence Gaps, Tolerability, and Implications for Clinical Practice.Drugs & aging · 2026Review
- Effects of Exercise Mode and Intensity on Retinal Microvascular Structure and Function in Heart Failure Patients with Preserved Ejection Fraction: A Pilot Exercise Intervention Trial.Journal of vascular research · 2026Article
- Transferrin Saturation Is a Better Predictor Than Ferritin of Metabolic and Hemodynamic Exercise Responses in HFpEF.JACC. Heart failure · 2025Article
- The Concept of "Heart Failure with Preserved Ejection Fraction": Time for a Critical Reappraisal.Reviews in cardiovascular medicine · 2023Review
- Review
- Heart Failure With Preserved Ejection Fraction: Current Status of Daily Clinical Practice in Indonesia.Cureus · 2023Article
- In Vitro Pressure Measurements Across an Interatrial Shunt for HFpEF Treatment.Cardiovascular engineering and technology · 2022Article
- Skeletal myopathy in a rat model of postmenopausal heart failure with preserved ejection fraction.Journal of applied physiology (Bethesda, Md. : 1985) · 2022Article
- Prefrailty, impairment in physical function, and risk of incident heart failure among older adults.Journal of the American Geriatrics Society · 2021Article
- Leukocyte count and the risk of adverse outcomes in patients with HFpEF.BMC cardiovascular disorders · 2021Article
- Article
- Relationships Between Objectively Measured Physical Activity, Exercise Capacity, and Quality of Life in Older Patients With Obese Heart Failure and Preserved Ejection Fraction.Journal of cardiac failure · 2021Article
- Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.Journal of cardiovascular translational research · 2021Review
- Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis.Frontiers in medicine · 2021Article
- BMI1 in the heart: Novel functions beyond tumorigenesis.EBioMedicine · 2021Review
- Heart failure with preserved ejection fraction: insights from recent clinical researches.The Korean journal of internal medicine · 2020Review
- Heart failure with preserved ejection fraction: New approaches to diagnosis and management.Clinical cardiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common form of HF. Among elderly women, HFpEF comprises more than 80% of incident HF cases. Adverse outcomes-exercise intolerance, poor quality of life, frequent hospitalizations, and reduced survival-approach those of classic HF with reduced EF (HFrEF). However, despite its importance, our understanding of the pathophysiology of HFpEF is incomplete, and despite intensive efforts, optimal therapy remains uncertain, as most trials to date have been negative. This is in stark contrast to management of HFrEF, where dozens of positive trials have established a broad array of effective, guidelines-based therapies that definitively improve a range of clinically meaningful outcomes. In addition to providing an overview of current management status, we examine evolving data that may help explain this paradox, overcome past challenges, provide a roadmap for future success, and that underpin a wave of new trials that will test novel approaches based on these insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.